Advertisement
Screener

Foghorn Therapeutics Inc. (FHTX) Graph

FHTX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $16.07M; Research and development $18.52M; Operating expenses $24.88M; Income tax (m).
  • 2026-03-31: Revenue $3.27M; Research and development $18.26M; Operating expenses $24.84M; Income tax (m).
  • 2025-12-31: Revenue $9.25M*; Research and development $22.05M*; Operating expenses $33.13M*; Income tax (m).
  • 2025-09-30: Revenue $8.15M; Research and development $20.00M; Operating expenses $26.65M; Income tax (m).

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

FHTX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.The Segment$16.07MRevenue$16.07MOperating expenses$24.88MOperating income-$8.80MResearch & development$18.52MNet income-$7.19M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$16.07M$18.52M$24.88M(m)-$7.19M
2026-03-31$3.27M$18.26M$24.84M(m)-$19.88M
2025-12-31$9.25M*$22.05M*$33.13M*(m)-$21.66M*
2025-09-30$8.15M$20.00M$26.65M(m)-$15.85M
2025-06-30$7.56M$21.79M$28.65M(m)-$17.94M
2025-03-31$5.95M$21.63M$28.86M(m)-$18.83M
2024-12-31(m)(m)(m)$0.00*(m)
2024-09-30$7.81M$24.69M$31.66M$0.00-$19.12M
2024-06-30$6.89M$23.80M$33.52M$0.00-$22.98M
2024-03-31$5.05M$25.53M$33.24M$0.00-$25.02M
2023-09-30$17.48M$26.25M$34.56M$738.00K-$14.35M
2023-06-30$5.60M$29.25M$37.65M$942.00K-$29.49M
2023-03-31$5.31M$29.98M$38.63M$560.00K-$30.49M
2022-09-30$6.63M$26.93M$34.89M$0.00-$25.77M
2022-06-30$4.49M$25.97M$33.68M$0.00-$27.31M
2022-03-31$3.92M$24.51M$31.72M$0.00-$26.91M
2021-09-30$41.00K$20.49M$26.30M(m)-$26.08M
2021-06-30$279.00K$18.64M$23.54M(m)-$23.11M
2021-03-31$286.00K$18.73M$23.42M(m)-$22.99M
2020-09-30$179.00K$16.11M$18.67M(m)-$18.37M
2020-06-30$0.00$13.63M$15.54M(m)-$15.72M
2020-03-31$0.00$11.50M$13.72M(m)-$13.95M
2019-09-30(m)$11.29M$13.10M(m)-$13.09M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$19.34M$36.78M$49.72M(m)-$27.07M
2025-06-30$13.51M$43.42M$57.52M(m)-$36.77M
2024-06-30$11.94M$49.33M$66.76M$0.00-$47.99M
2023-06-30$10.91M$59.23M$76.28M$1.50M-$59.98M
2022-06-30$8.41M$50.48M$65.40M$0.00-$54.23M
2021-06-30$565.00K$37.37M$46.96M(m)-$46.10M
2020-06-30$0.00$25.13M$29.26M(m)-$29.68M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$21.66M$63.42M$84.17M(m)-$52.62M
2024-09-30$19.75M$74.02M$98.42M$0.00-$67.12M
2023-09-30$28.39M$85.48M$110.83M$2.24M-$74.32M
2022-09-30$15.04M$77.41M$100.30M$0.00-$80.00M
2021-09-30$606.00K$57.86M$73.26M(m)-$72.18M
2020-09-30$179.00K$41.24M$47.93M(m)-$48.04M
2019-09-30(m)$30.84M$35.90M(m)-$35.84M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$30.91M$85.47M$117.30M$0.00-$74.28M
2024-12-31$22.60M$94.53M$125.28M$0.00-$86.62M
2023-12-31$34.16M$109.69M$142.06M$4.23M-$98.43M
2022-12-31$19.23M$105.62M$136.37M$0.00-$108.88M
2021-12-31$1.32M$80.33M$102.05M(m)-$101.32M
2020-12-31$430.00K$57.72M$68.96M$0.00-$68.80M
2019-12-31(m)$44.36M$51.08M$0.00-$51.13M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Nkarta, Inc. (NKTX)United States$0.205B-1.73
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37